



# MORE CHOICES, MORE ANSWERS »

MicroScan Gram-negative  
and Gram-positive panels

MicroScan Microbiology Systems



» Move healthcare forward.



## LABORATORIES ON THE FRONT LINE

Misuse and overuse of antibiotics is a significant factor in the development of antimicrobial resistance, which is recognized as one of the most serious health threats both in the U.S. and worldwide.<sup>1</sup> Inappropriate antibiotic use reduces the therapeutic effectiveness of essential drugs and increases the development and spread of multidrug-resistant organisms. National and global organizations are promoting collaboration in healthcare settings and education about appropriate antimicrobial usage to halt the spread of emerging resistance.

Experts agree that the role of the laboratory has never been more important in helping curb the threats of “superbug” endemic reservoirs and epidemics worldwide as evidenced by:

- › The National Action Plan for Combating Antibiotic Resistant Bacteria
- › The CDC-developed Carbapenem-resistant Enterobacteriaceae (CRE) Control and Prevention Toolkit
- › Global CRE research and prevention initiatives

**For over 35 years, MicroScan panels have provided gold-standard bacterial identification and susceptibility products, confronting emerging resistance head on.**

MicroScan panels provide **FIRST-TIME ACCURACY** with direct MIC for **TRUSTED DETECTION** of emerging and critical antimicrobial resistance to help you **AVOID DELAYS** associated with extra confirmatory testing and real-time alerts to **ENABLE IMMEDIATE ACTION.**

### Antimicrobial stewardship: collaboration is key

The primary goal of antimicrobial stewardship programs is to optimize antimicrobial dosing, duration and route of administration for each patient while minimizing adverse drug events and the emergence of antimicrobial resistance.<sup>2,3</sup> Microbiologists play an integral role in stewardship programs by proactively reporting critical or unusual results. They also generate various epidemiology reports and antibiogram data to:

- > Guide empiric therapy choices
- > Provide information for therapeutic formulary decisions
- > Track changes in susceptibility patterns and bacterial incidence to identify emerging resistance
- > Direct infection control investigations
- > Determine effectiveness of infection control practices



Accurate MicroScan AST results are the foundation of the antibiogram data that clinicians rely on for patient management.

**“Antibiograms play a key role in identifying local and interdepartmental trends in antibiotic susceptibility or resistance. These data are important not only in devising best-treatment practices for the institution, but also in evaluating the impact of a recently implemented ASP (antimicrobial stewardship program).”<sup>4</sup>**



## CRE: AN URGENT HEALTH THREAT

The occurrence of *Klebsiella pneumoniae* carbapenemase (KPC), the most prevalent form of CRE, is endemic. The resistance mechanism in KPCs is plasmid-mediated, meaning it is easily transferrable between strains, species, genera, patients and facilities. Within the laboratory, it is crucial to run antimicrobial susceptibility tests on any identified Gram-negative bacteria to determine if the strain is a CRE. **MicroScan has demonstrated exceptional accuracy for the detection of carbapenem resistance in multicenter studies.**<sup>5,6</sup>

MicroScan's latest Gram-negative panels offer an enhanced testing menu.

- › Carbapenem dilutions encompass CLSI and FDA breakpoints
- › Lower dilutions of select antibiotics support evaluation of alternative therapeutic dosing regimens
- › Additional oral drugs provide options for step-down therapies and outpatient management
- › Additional MIC panel selections complement workflows for laboratories choosing to integrate MALDI-TOF identifications or those desiring additional resistance testing

## Gram-negative MIC panels

Panel name	Neg MIC 42	Neg MIC 43	Neg MIC 45	Neg MIC 46	ES $\beta$ L <i>plus</i>	
MicroScan catalog number	B1017-419	B1017-420	B1017-424	B1017-425	B1027-101	
Languages	EN, ES, FR, PT					
Antimicrobial agent	$\mu$ g/mL	Abbr.				
Amikacin	4-32	8-32	16-32	4-32	-	Ak
Amoxicillin/K Clavulanate	8/4-16/8	8/4-16/8	4/2-16/8	4/2-16/8	-	Aug
Ampicillin	2-16	2-16	8-16	8-16	-	Am
Ampicillin/Sulbactam	4/2-16/8	4/2-16/8	1/0.5-16/8	4/2-16/8	-	A/S
Aztreonam	2-16	4-16	4-16	4-16	0.5-64	Azt
Cefazolin	2-16	2-16	2-16	2-16	-	Cfz
Cefepime	2-16	2-16	2-16	2-16	1-32	Cpe
ES $\beta$ L Screen - Cefotaxime	-	-	1	1	-	CftE
Cefotaxime*	2-32	2-32	2-32	2-32	0.5-128	Cft
ES $\beta$ L Confirmation - Cefotaxime/K Clavulanate	-	0.5/4, 4/4	0.5/4, 4/4	-	0.12/4-16/4	Cft/CA
Cefotetan	-	-	-	16-32	1-32	Ctn
Cefoxitin	2-16	4-16	8-16	-	2-32	Cfx
Cefpodoxime	-	-	-	2-4	0.5-64	Cpd
Ceftazidime*	2-16	1, 4-16	1-16	2-16	0.5-128	Caz
ES $\beta$ L Confirmation - Ceftazidime/K Clavulanate	-	0.25/4, 2/4	0.25/4, 2/4	-	0.12/4-16/4	Cft/CA
Ceftriaxone	1-2, 8, 32	1-2, 8, 32	1-32	1-32	1-64	Cax
Cefuroxime	4-16	4-16	4-16	4-16	-	Crn
Cephalothin	8-16	8-16	-	-	-	Cf
Chloramphenicol	-	-	-	8-16	-	C
Ciprofloxacin	0.5-4	0.5-2	1-2	1-2	-	Cp
Doripenem	0.5-2	-	-	0.5-2	-	Dor
Ertapenem	0.5-4	0.5-4	0.5-1	0.5-1	-	Etp
Gentamicin	1-8	1-8	1-8	1-8	-	Gm
Imipenem	1-8	1-8	0.5-8	1-8	0.5-16	Imp
Levofloxacin	0.5-4	1-4	0.25-4	1-4	-	Lvx
Meropenem	1-8	1-8	1-8	1-8	0.5-16	Mer
Moxifloxacin	-	2-4	-	2-4	-	Mxf
Nitrofurantoin	32-64	32-64	32-64	32-64	-	Fd
Piperacillin	-	16-64	16, 64	-	16-64	Pi
Piperacillin/Tazobactam	8-64	8-64	4-64	8-64	-	P/T
Tetracycline	2-8	2-8	4-8	4-8	-	Te
Ticarcillin/K Clavulanate	-	-	8-64	8-64	-	Tim
Tigecycline	1-4	1-4	2-4	1-4	-	Tgc
Tobramycin	1-8	2-8	1-8	1-8	-	To
Trimethoprim	-	-	-	8	-	T
Trimethoprim/Sulfamethoxazole	0.5/9.5-2/38	0.5/9.5-2/38	2/38	2/38	-	T/S
<b>Total antibiotic tests/panel</b>	<b>26</b>	<b>28</b>	<b>27</b>	<b>31</b>	<b>12</b>	

### Legend

EN: English, ES: Spanish, FR: French, PT: Portuguese

## Gram-negative combo panels

Panel name	Neg Combo 67	Neg Combo 68	Neg/Urine Combo 51	Neg/Urine Combo 55	Neg/Urine Combo 61	Neg/Urine Combo 62	Neg/Urine Combo 73
MicroScan catalog number	B1017-421	B1017-422	B1017-407	B1017-409	B1017-414	B1017-416	B1017-423
Languages	EN, ES, FR, PT	EN, ES, FR, PT	EN, ES, FR, P T	EN, ES, FR, PT			
Antimicrobial agent	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL
Amikacin	8-32	16-32	16-32	16-32	16-32	16-32	16-32
Amoxicillin/K Clavulanate	–	8/4-16/8	8/4-16/8	–	–	–	8/4-16/8
Ampicillin	4-16	8-16	8-16	8-16	8-16	8-16	8-16
Ampicillin/Sulbactam	4/2-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8
Aztreonam	4-16	–	–	8-16	4-16	4-16	4-16
Cefazolin	4-16	2-4	8-16	–	8-16	8-16	2-4
Cefepime	1-16	4-16	4-16	8-16	4-16	4-16	8-16
Cefixime	–	–	–	–	–	–	–
ESβL Screen - Cefotaxime	–	–	–	–	–	–	–
Cefotaxime*	2, 16	2, 8-32	2, 8-32	2, 8-32	2, 8-32	2, 8-32	2, 8-32
ESβL Confirmation - Cefotaxime/K Clavulanate	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4
Cefotetan	–	–	–	16-32	–	–	–
Cefoxitin	–	–	–	–	8-16	8-16	–
Cefpodoxime	–	–	–	–	–	–	–
Ceftazidime*	1, 8	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16
ESβL Confirmation - Ceftazidime/K Clavulanate	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4
Ceftriaxone	1-8	1-2, 8, 32	8-32	8, 32	1-2, 8, 32	8, 32	1-2, 8, 32
Cefuroxime	4-16	4-16	4-16	4-16	4-16	4-16	4-16
Cephalothin	–	–	–	8-16	–	–	8-16
Ciprofloxacin	0.5-2	1-2	1-4	1-2	1-2	1-2	1-2
Doripenem	–	–	–	–	–	0.5-2	–
Ertapenem	0.5-1	0.5-2	2-4	1-4	1-4	1-4	0.5-1
Gentamicin	2-8	2-8	4-8	4-8	4-8	4-8	2-8
Imipenem	–	1-8	1-8	1-8	1-8	–	1-8
Levofloxacin	1-4	2-4	2-4	2-4	2-4	2-4	2-4
Meropenem	1-8	1-8	1-8	1-8	1-8	1-8	–
Moxifloxacin	–	–	2-4	–	–	–	–
Nitrofurantoin	–	–	32-64	32-64	32-64	32-64	32-64
Piperacillin	–	–	–	16-64	–	–	–
Piperacillin/Tazobactam	16-64	16-64	16, 64	16, 64	16, 64	16, 64	16-64
Tetracycline	2-8	4-8	4-8	4-8	–	4-8	4-8
Ticarcillin/K Clavulanate	–	–	16, 64	–	–	–	16, 64
Tigecycline	–	2-4	–	2-4	2-4	1-4	–
Tobramycin	2-8	4-8	4-8	4-8	4-8	4-8	4-8
Trimethoprim	–	–	–	–	–	–	8
Trimethoprim/Sulfamethoxazole	2/38	2/38	2/38	2/38	2/38	2/38	2/38
<b>Total antibiotic tests/panel</b>	<b>18</b>	<b>22</b>	<b>24</b>	<b>25</b>	<b>23</b>	<b>24</b>	<b>25</b>

### Legend

EN: English, ES: Spanish, FR: French, PT: Portuguese

Neg/Urine Combo 74	Neg/Urine Combo 75	Neg/Urine Combo 76	Neg/Urine Combo 77	Neg/Urine Combo 78	Neg/Urine Combo 79	Neg BP Combo 34	Neg BP Combo 44	Neg BP Combo 47	
B1017-426	B1017-427	B1017-428	B1017-429	B1017-430	B1017-431	B1017-404	B1017-411	B1017-417	
EN, ES, FR, PT	EN, ES, FR, PT	EN, ES, FR, PT	EN, ES, FR, PT						
µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	Abbr.
-	8-32	4-32	16-32	-	8-32	16-32	16-32	16-32	Ak
8/4-16/8	8/4-16/8	-	8/4-16/8	8/4-16/8	-	8/4-16/8	8/4-16/8	8/4-16/8	Aug
8-16	8-16	-	8-16	-	8-16	8-16	8-16	8-16	Am
8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	8/4-16/8	A/S
4-16	4-16	4-16	-	4-16	4-16	8-16	8-16	8-16	Azt
2-4, 16	2-16	2-16	2-16	2-16	2-16	8-16	8-16	8-16	Cfz
2-16	2-16	2-16	2-16	2-16	2-16	8-16	8-16	8-16	Cpe
1-2	-	-	-	-	-	-	-	-	Cfe
-	1	1	1	-	-	-	-	-	CftE
2, 16	2-32	2-32	2-32	2, 16	2, 8-32	2, 8-32	2, 8-32	2, 8-32	Cft
0.5/4, 4/4	0.5/4, 4/4	-	-	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	0.5/4, 4/4	Cft/ CA
-	-	-	-	16-32	-	16-32	-	-	Ctn
8-16	8-16	8-16	-	-	-	8-16	8-16	8-16	Cfx
2-4	-	-	-	-	-	-	-	-	Cpd
1, 4-16	1, 4-16	4-16	4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	1, 4-16	Caz
0.25/4, 2/4	0.25/4, 2/4	-	-	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	0.25/4, 2/4	Caz/ CA
1-2, 8, 32	1-2, 8, 32	1-2, 8, 32	1-32	1-2, 8, 32	-	8, 32	8, 32	8, 32	Cax
4-16	4-16	-	4-16	4-16	2-16	4-16	4-16	4-16	Crm
-	-	-	-	-	-	8-16	8-16	-	Cf
1-2	1-2	1-2	1-2	1-2	1-2	1-2	1-2	1-2	Cp
-	-	-	0.5-2	-	-	-	-	0.5-2	Dor
0.5-1	0.5-1	0.5-1	0.5-1	0.5-1	0.5-1	2-4	1-4	1-4	Etp
4-8	4-8	2-8	4-8	1-8	4-8	4-8	4-8	4-8	Gm
1-8	-	1-8	1-8	1-8	1-8	4-8	4-8	1-8	Imp
2-4	-	2-4	2-4	-	2-4	2-4	2-4	2-4	Lvx
-	1-8	1-8	-	1-8	0.5-8	4-8	4-8	-	Mer
-	-	-	-	-	-	2-4	-	-	Mxf
32-64	32-64	32-64	32-64	32-64	32-64	32-64	32-64	32-64	Fd
-	-	-	-	-	16, 64	-	16-64	-	Pi
16, 64	16-64	16-64	16-64	16-64	16, 64	16, 64	16, 64	16, 64	P/T
4-8	-	-	4-8	-	-	4-8	4-8	4-8	Te
-	-	-	-	-	-	16, 64	-	-	Tim
-	-	2-4	2-4	2-4	2-4	-	2-4	2-4	Tgc
4-8	4-8	1-8	4-8	2-8	-	4-8	4-8	4-8	To
8	-	-	-	-	-	-	-	-	T
2/38	2/38	2/38	2/38	2/38	2/38	2/38	2/38	2/38	T/S
<b>25</b>	<b>21</b>	<b>21</b>	<b>23</b>	<b>21</b>	<b>21</b>	<b>28</b>	<b>27</b>	<b>25</b>	



## MRSA: A SERIOUS HEALTH THREAT

Methicillin-resistant *Staphylococcus aureus* (MRSA) outbreaks have been reported by the media for more than a decade. Goals and strategies outlined in the president's 2015 National Action Plan for Combating Antibiotic Resistant Bacteria are intended to significantly reduce the incidence of urgent and serious threats, including MRSA, by 2020.

### **MicroScan's latest Gram-positive panels offer an enhanced testing menu.**

- › Ceftaroline<sup>†</sup>: a new broad-spectrum cephalosporin with anti-MRSA activity for use in acute bacterial skin and skin structure infections (ABSSSI)
- › Tigecycline<sup>†</sup>: a glycycline antibiotic not affected by major in-class resistance mechanisms with anti-MRSA activity
- › Enhanced formulation of vancomycin improves performance when using the Prompt<sup>®</sup> Inoculation System for *Staphylococcus aureus* testing
- › MIC panel selections complement workflows for laboratories choosing to integrate MALDI-TOF identifications or those desiring additional resistance testing

---

**MicroScan is the first to offer ceftaroline on an automated susceptibility panel.**

## Gram-positive MIC panels

Panel name	Pos MIC 29	Pos MIC 34	MICroSTREP plus 1	MICroSTREP plus 2	
MicroScan catalog number	B1017-212	B1017-216	B1027-201	B1027-202	
Languages	EN, ES, FR, PT	EN, ES, FR, PT	EN, ES, FR, PT	EN, ES, FR, PT	
Antimicrobial agent	µg/mL	µg/mL	µg/mL	µg/mL	Abbr.
Amoxicillin/K Clavulanate	4/2	-	0.5/0.25-4/2	0.5/0.25-4/2	Aug
Ampicillin	2-8	2-8	0.06-4	0.06-4	Am
Ampicillin/Sulbactam	8/4-16/8	-	-	-	A/S
Azithromycin	-	-	0.25-2	0.5-2	Azi
Cefaclor	-	-	0.5-4	0.5-4	Cfr
Cefazolin	4-16	4-16	-	-	Cfz
Cefepime	-	-	0.25-2	0.25-2	Cpe
Cefotaxime	-	-	0.25-2	0.25-2	Cft
Cefoxitin Screen	4	4	-	-	CfxS
Ceftaroline	-	0.5-4	-	-	Cpt
Ceftriaxone	4-32	4-32	0.25-2	0.25-2	Cax
Cefuroxime	-	-	0.25-2	0.25-2	Crm
Chloramphenicol	8-16	8-16	1-16	1-16	C
Ciprofloxacin	1-2	1-2	-	-	Cp
Clarithromycin	-	-	-	0.25-1	Cla
Clindamycin	0.25-4	0.25-4	0.06-0.5	0.06-0.5	Cd
Daptomycin	0.25-4	0.25-4	-	0.25-2	Dap
Erythromycin	0.25-4	0.25-4	0.06-0.5	0.06-0.5	E
Gatifloxacin	-	-	0.12-2	-	Gat
Gentamicin	1-8	1-8	-	-	Gm
Gentamicin Synergy Screen	500	500	-	-	GmS
Imipenem	4-8	-	-	-	Imp
Inducible Clindamycin Test	4/0.5	4/0.5	-	-	ICd
Levofloxacin	0.5-4	0.5-4	0.25-4	0.25-4	Lvx
Linezolid	0.5-4	0.5-4	-	0.5-4	Lzd
Meropenem	2-8	-	0.06-0.5	0.06-0.5	Mer
Moxifloxacin	0.5-4	0.25-4	-	0.25-4	Mxf
Nitrofurantoin	32-64	32-64	-	-	Fd
Oxacillin	0.25-2	0.25-2	-	-	Ox
Penicillin	0.03-8	0.03-8	0.03-4	0.03-4	P
Rifampin	1-2	1-2	-	-	Rif
Streptomycin Synergy Screen	1000	1000	-	-	StS
Synercid	0.25-2	0.25-2	-	-	Syn
Tetracycline	1-8	2-8	0.5-4	0.5-4	Te
Tigecycline	-	0.12-1	-	-	Tgc
Trimethoprim/ Sulfamethoxazole	0.5/9.5-2/38	0.5/9.5-2/38	0.25/4.75-2/38	0.25/4.75-2/38	T/S
Vancomycin	0.25-16	0.25-16	0.12-1	0.12-4	Va
<b>Total antibiotic tests/panel</b>	<b>28</b>	<b>26</b>	<b>18</b>	<b>21</b>	

### Legend

EN: English, ES: Spanish, FR: French, PT: Portuguese

## Gram-positive combo panels

Panel name	Pos Combo 29	Pos Combo 33	Pos Combo 34	Pos Combo 43	Pos Combo 44	Pos BP Combo 20	
MicroScan catalog number	B1017-209	B1017-211	B1017-214	B1017-217	B1017-218	B1017-202	
Languages	EN, ES, FR, PT	EN, ES, FR, PT					
Antimicrobial agent	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	µg/mL	Abbr.
Amoxicillin/K Clavulanate	4/2	4/2	4/2	-	4/2	4/2	Aug
Ampicillin	2-8	2-8	2-8	2-8	2-8	0.25, 2-8	Am
Ampicillin/Sulbactam	8/4-16/8	8/4-16/8	8/4-16/8	-	8/4-16/8	8/4-16/8	A/S
Azithromycin	-	-	-	-	2-4	2-4	Azi
Cefazolin	8-16	-	4-16	-	8-16	8-16	Cfz
Cefepime	-	-	-	-	-	8-16	Cpe
Cefotaxime	-	-	-	-	-	8, 32	Cft
Cefoxitin Screen	-	4	4	4	4	-	CfxS
Ceftaroline	-	-	-	0.5-4	0.5-2	-	Cpt
Ceftriaxone	8, 32	8, 32	-	-	-	8, 32	Cax
Cephalothin	-	-	-	-	-	8-16	Cf
Chloramphenicol	8-16	-	-	-	8-16	8-16	C
Ciprofloxacin	-	1-2	1-2	1-2	1-2	1-2	Cp
Clindamycin	0.5-4	0.5-4	0.5-4	0.5-4	0.25-0.5, 2	0.5, 2	Cd
Daptomycin	0.5-4	0.5-4	0.5-4	0.5-4	1, 4	-	Dap
Erythromycin	0.5-4	0.5-4	0.5-4	0.5-4	0.5-4	0.5, 4	E
Gatifloxacin	-	-	-	-	-	2-4	Gat
Gentamicin	4-8	4-8	4-8	4-8	4-8	4-8	Gm
Gentamicin Synergy Screen	500	500	500	500	500	500	GmS
Imipenem	4-8	-	-	-	-	4-8	Imp
Inducible Clindamycin Test	-	4/0.5	4/0.5	4/0.5	4/0.5	-	ICd
Levofloxacin	2-4	1-4	1-4	1-4	1-4	2-4	Lvx
Linezolid	1-4	1-4	1-4	1-4	2-4	2-4	Lzd
Meropenem	4-8	-	-	-	-	-	Mer
Moxifloxacin	2-4	0.5-4	0.5-4	0.5, 2-4	0.5-1, 4	2-4	Mxf
Nitrofurantoin	32-64	32-64	32-64	32-64	32-64	32-64	Fd
Norfloxacin	-	-	-	-	-	4-8	Nxn
Ofloxacin	-	-	-	-	-	2-4	Ofl
Oxacillin	0.25-2	0.25-2	0.25-2	0.25-2	0.25, 1-2	0.25, 1-2	Ox
Penicillin	0.03, 0.12-0.25, 2, 8	0.03, 0.12-0.25, 2, 8	0.03, 0.12-0.25, 2, 8	0.03, 0.12-0.25, 2, 8	0.03, 0.12-0.25, 2, 8	0.03, 0.12, 2, 8	P
Piperacillin/Tazobactam	-	-	-	-	-	4-8	P/T
Rifampin	1-2	1-2	1-2	1-2	1-2	1-2	Rif
Streptomycin Synergy Screen	1000	1000	1000	1000	1000	1000	StS
Synercid	0.5-2	0.5-2	1-2	1-2	0.5-2	1-2	Syn
Tetracycline	4-8	4-8	4-8	4-8	4-8	4-8	Te
Tigecycline	-	-	-	0.25-1	-	-	Tgc
Trimethoprim/Sulfamethoxazole	0.5/9.5, 2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	0.5/9.5-2/38	2/38	T/S
Vancomycin	0.25-16	0.25-16	0.25-16	0.25-16	0.5-16	2-4, 16	Va
<b>Total antibiotic tests/panel</b>	<b>25</b>	<b>24</b>	<b>24</b>	<b>23</b>	<b>27</b>	<b>32</b>	

### Legend

EN: English, ES: Spanish, FR: French, PT: Portuguese



# FLEXIBLE IDENTIFICATION OPTIONS

**MicroScan's broad selection of identification panels ensures accurate identification of clinically significant species and supports either overnight or rapid workflow requirements.**

Conventional overnight panel identifications are based on classical biochemical substrates and can be automatically processed on the **WalkAway** and **autoSCAN-4** systems or visually interpreted. Identifications for most species are available in 16 to 18 hours. For over 35 years, **MicroScan panels have provided gold-standard bacterial identification and susceptibility testing**, confronting emerging resistance head-on.

Product #	Name	Species	Type and database	Agreement to reference
B1017-27	Neg ID Type 2	136	Fermentative and non-fermentative gram-negative bacilli	98.3%
B1017-221	Pos ID Type 3	25	<i>Micrococcaceae</i> including <i>Staphylococcus</i> , <i>Micrococcus</i> , related species and <i>Listeria monocytogenes</i>	99.1%
		26	<i>Streptococcaceae</i> , including <i>Streptococcus</i> , <i>Enterococcus</i> and related species	99.7%

Rapid panels require processing in a WalkAway system because they use fluorogenic substrates and indicators. Identifications are available in two-and-a-half hours and require no or minimal reagents.<sup>§</sup>

Product #	Name	Species	Type and database	Agreement to reference <sup>  </sup>
B1017-110	Rapid Neg ID 3 <sup>§</sup>	77	Fermentative, Gram-negative bacilli	98.9%
		43	Non-fermentative, Gram-negative bacilli	98.1%
B1017-165	Rapid Neg ID 4	72	Fermentative, Gram-negative bacilli	98.8%
		48	Non-fermentative, Gram-negative bacilli	97.7%
B1017-166	Rapid Pos ID 2	24	<i>Micrococcaceae</i> including <i>Staphylococcus</i> , <i>Micrococcus</i> , related species and <i>Listeria monocytogenes</i> and <i>Listeria innocua/seeligeri</i>	99.7%
		29	<i>Streptococcaceae</i> , including <i>Streptococcus</i> , <i>Enterococcus</i> and related species	99.4%



## BROAD MENU OF ANTIBIOTIC CONFIGURATIONS

MicroScan's portfolio of identification and antimicrobial susceptibility panels supports unique institutional or geographic needs by providing a broad menu of antibiotic configurations, choice of antimicrobial susceptibility test formats and inoculum preparation methods, and both traditional overnight or rapid identifications.

With the continued emergence of antimicrobial resistance, **our direct testing methodology provides the most accurate and sensitive method for detecting subtle changes in susceptibility results.**

---

**Count on MicroScan for unmatched experience, expertise and selection.**

### References

1. Moody, J, Cosgrove, SE, Olmstead, R, et al. Antimicrobial Stewardship: A collaborative partnership between infection Preventionists and health care epidemiologists. *Am J Infect Control.* 2012;40(2):94-5.
2. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional programs to enhance antimicrobial stewardship. *Clin Infect Dis.* 2007;44(2):159-77.
3. Policy statement on antimicrobial stewardship by SHEA/IDSA/PIDS. *Infect Control Hosp Epidemiol.* 2012;33(4):322-7.
4. Goff, DA. Antimicrobial stewardship: bridging the gap between quality care and cost. *Curr Opin Infect Dis.* 2011;24 Suppl 1:S11-20.
5. Bulik, CC et al. Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing *Klebsiella pneumoniae* Isolates by Various Testing Methods. *J Clin Microbiol.* 2010;48(7):2402-6.
6. Harino, T et al. Meropenem Resistance in Imipenem-Susceptible Meropenem-Resistant *Klebsiella pneumoniae* Isolates Not Detected by Rapid Automated Testing Systems. *J Clin Microbiol.* 2013;51(8):2735-8.

\* Dilutions used with streamlined ESBL Confirmation test: Cefotaxime 2, 16 Ceftazidime 1, 8

† Ceftriaxone fosamil is sold in the United States as Teflaro® by Forest Pharmaceuticals, Inc., an Allergan affiliate.

‡ Tigecycline is sold under the trademark name TYGACIL® by Pfizer, Inc.

§ Requires use of Rapid Indole reagent.

|| Internal development data

PROMPT is a registered trademark of 3M.

©2016 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service names mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For Beckman Coulter's worldwide office locations and phone numbers, please visit [www.beckmancoulter.com/contact](http://www.beckmancoulter.com/contact)

BR-51688



 Move healthcare forward.